Infectious disease biotech Arsanis files for a $58 million IPO
Arsanis, which is developing antibodies designed to prevent serious infectious diseases, filed on Friday with the SEC to raise up to $58 million in an initial public offering.
The Waltham, MA-based company was founded in 2010 and plans to list on the Nasdaq under the symbol ASNS. Arsanis filed confidentially on August 10, 2017. Citi, Cowen & Company and Piper Jaffray are the joint bookrunners on the deal. No pricing terms were disclosed.
The article Infectious disease biotech Arsanis files for a $58 million IPO originally appeared on IPO investment manager Renaissance Capital's web site renaissancecapital.com.
Investment Disclosure: The information and opinions expressed herein were prepared by Renaissance Capital's research analysts and do not constitute an offer to buy or sell any security. Renaissance Capital, the Renaissance IPO ETF (symbol: IPO) or the Global IPO Fund (symbol: IPOSX) , may have investments in securities of companies mentioned.